Viramune nevirapine non-nucleoside reverse transcriptase inhibitor data

Results from a triple combination therapy open-label Phase I/II trial in 8 infants aged 2.5 to

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE